Mitochondrial dynamics, a new therapeutic target for Triple Negative Breast Cancer

被引:43
作者
Weiner-Gorzel, K. [1 ,2 ]
Murphy, M. [1 ]
机构
[1] Univ Coll Dublin, UCD Sch Med, Conway Inst, Dublin, Ireland
[2] St Vincent Univ Hosp, Dept Gen Med, Elm Pk, Dublin, Ireland
来源
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER | 2021年 / 1875卷 / 02期
关键词
ENHANCES AEROBIC GLYCOLYSIS; ESTROGEN-RELATED RECEPTOR; FISSION; CELLS; GROWTH; COMBINATION; MIGRATION; PATHWAY; FUSION; TRIAL;
D O I
10.1016/j.bbcan.2021.188518
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Triple Negative Breast Cancer (TNBC) is an aggressive tumour with patients survival rarely exceeding five years. TNBC tumours are larger in size, more chemoresistant, highly proliferative and usually more enriched in stem and immune cells comparing to other breast cancer subtypes. Functionally, these changes are dependent on a high-quality mitochondrial pool. Mitochondrial health is constantly assessed and appropriately improved by mitochondrial dynamics (cycles of mitochondrial fusion and division). Recent advances in understanding of mitochondrial dynamics in TNBC has demonstrated its critical importance in tumour growth and metastasis. This review explores current knowledge of mitochondrial dynamics in TNBC and discusses targeting this pathway clinically to improve outcomes for patients.
引用
收藏
页数:7
相关论文
共 74 条
[1]   Prospective identification of tumorigenic breast cancer cells [J].
Al-Hajj, M ;
Wicha, MS ;
Benito-Hernandez, A ;
Morrison, SJ ;
Clarke, MF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (07) :3983-3988
[2]   Metastatic and triple-negative breast cancer: challenges and treatment options [J].
Al-Mahmood, Sumayah ;
Sapiezynski, Justin ;
Garbuzenko, Olga B. ;
Minko, Tamara .
DRUG DELIVERY AND TRANSLATIONAL RESEARCH, 2018, 8 (05) :1483-1507
[3]  
[Anonymous], 2019, STEM CELLS INT, V2019
[4]  
[Anonymous], 2018, ANTIOXIDANTS BASEL S, V7
[5]   Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab [J].
Basho, Reva K. ;
Gilcrease, Michael ;
Murthy, Rashmi K. ;
Helgason, Thorunn ;
Karp, Daniel D. ;
Meric-Bernstam, Funda ;
Hess, Kenneth R. ;
Herbrich, Shelley M. ;
Valero, Vicente ;
Albarracin, Constance ;
Litton, Jennifer K. ;
Chavez-MacGregor, Mariana ;
Ibrahim, Nuhad K. ;
Murray, James L., III ;
Koenig, Kimberly B. ;
Hong, David ;
Subbiah, Vivek ;
Kurzrock, Razelle ;
Janku, Filip ;
Moulder, Stacy L. .
JAMA ONCOLOGY, 2017, 3 (04) :509-515
[6]   Adaptive Reprogramming of De Novo Pyrimidine Synthesis Is a Metabolic Vulnerability in Triple-Negative Breast Cancer [J].
Brown, Kristin K. ;
Spinelli, Jessica B. ;
Asara, John M. ;
Toker, Alex .
CANCER DISCOVERY, 2017, 7 (04) :391-399
[7]   Triple negative breast cancer: special histological types and emerging therapeutic methods [J].
Cao, Lu ;
Niu, Yun .
CANCER BIOLOGY & MEDICINE, 2020, 17 (02) :293-306
[8]   Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members [J].
Certo, Michael ;
Moore, Victoria Del Gaizo ;
Nishino, Mari ;
Wei, Guo ;
Korsmeyer, Stanley ;
Armstrong, Scott A. ;
Letai, Anthony .
CANCER CELL, 2006, 9 (05) :351-365
[9]   Antitumor Actions of Intratumoral Delivery of Membrane-Fused Mitochondria in a Mouse Model of Triple-Negative Breast Cancers [J].
Chang, Jui-Chih ;
Chang, Huei-Shin ;
Wu, Yao-Chung ;
Cheng, Wen-Ling ;
Lin, Ta-Tsung ;
Chang, Hui-Ju ;
Chen, Shou-Tung ;
Liu, Chin-San .
ONCOTARGETS AND THERAPY, 2020, 13 :5241-5255
[10]   Mitochondrial transplantation regulates antitumour activity, chemoresistance and mitochondrial dynamics in breast cancer [J].
Chang, Jui-Chih ;
Chang, Huei-Shin ;
Wu, Yao-Chung ;
Cheng, Wen-Ling ;
Lin, Ta-Tsung ;
Chang, Hui-Ju ;
Kuo, Shou-Jen ;
Chen, Shou-Tung ;
Liu, Chin-San .
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2019, 38 (1)